Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models - PubMed (original) (raw)
. 1998 Feb;284(2):687-92.
Affiliations
- PMID: 9454815
Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models
J R Jackson et al. J Pharmacol Exp Ther. 1998 Feb.
Abstract
Chronic inflammatory diseases often are accompanied by intense angiogenesis, supporting the destructive proliferation of inflammatory tissues. A model of inflammatory angiogenesis is the murine air pouch granuloma, which has a hyperangiogenic component. In this model, we explored the regulation of inflammatory angiogenesis using SB 220025, a specific inhibitor of human p38 mitogen-activated protein (MAP) kinase, with an IC50 value of 60 nM and 50- to 1000-fold selectivity vs. other kinases tested. In vivo, this compound reduced the lipopolysaccharide-induced production of tumor necrosis factor at an ED50 value of 7.5 mg/kg. In the inflammatory angiogenesis model, over the course of granuloma development, we observed elevated levels of interleukin-1beta and tumor necrosis factor-alpha during the chronic inflammatory phase when intense angiogenesis occurs. SB 220025 at 30 mg/kg b.i.d. p.o. was able to greatly reduce the expression of these cytokines and inhibit angiogenesis by approximately 40%. To further study the effects of p38/CSBP MAP kinase inhibition in angiogenesis-dependent chronic inflammatory disease, SB 220025 was tested in murine collagen-induced arthritis. In this model, SB 220025 was able to prevent the progression of established arthritis. Thus, this p38/CSBP MAP kinase inhibitor, which can reduce inflammatory cytokine production and inhibit angiogenesis, is an effective treatment for chronic proliferative inflammatory disease.
Similar articles
- SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence.
Underwood DC, Osborn RR, Kotzer CJ, Adams JL, Lee JC, Webb EF, Carpenter DC, Bochnowicz S, Thomas HC, Hay DW, Griswold DE. Underwood DC, et al. J Pharmacol Exp Ther. 2000 Apr;293(1):281-8. J Pharmacol Exp Ther. 2000. PMID: 10734180 - Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation.
Hope HR, Anderson GD, Burnette BL, Compton RP, Devraj RV, Hirsch JL, Keith RH, Li X, Mbalaviele G, Messing DM, Saabye MJ, Schindler JF, Selness SR, Stillwell LI, Webb EG, Zhang J, Monahan JB. Hope HR, et al. J Pharmacol Exp Ther. 2009 Dec;331(3):882-95. doi: 10.1124/jpet.109.158329. Epub 2009 Aug 31. J Pharmacol Exp Ther. 2009. PMID: 19720877 Clinical Trial. - Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.
Liverton NJ, Butcher JW, Claiborne CF, Claremon DA, Libby BE, Nguyen KT, Pitzenberger SM, Selnick HG, Smith GR, Tebben A, Vacca JP, Varga SL, Agarwal L, Dancheck K, Forsyth AJ, Fletcher DS, Frantz B, Hanlon WA, Harper CF, Hofsess SJ, Kostura M, Lin J, Luell S, O'Neill EA, O'Keefe SJ, et al. Liverton NJ, et al. J Med Chem. 1999 Jun 17;42(12):2180-90. doi: 10.1021/jm9805236. J Med Chem. 1999. PMID: 10377223 - Kinase inhibitors and airway inflammation.
Adcock IM, Chung KF, Caramori G, Ito K. Adcock IM, et al. Eur J Pharmacol. 2006 Mar 8;533(1-3):118-32. doi: 10.1016/j.ejphar.2005.12.054. Epub 2006 Feb 8. Eur J Pharmacol. 2006. PMID: 16469308 Retracted. Review. - Inhibitors of p38 MAP kinase: therapeutic intervention in cytokine-mediated diseases.
Salituro FG, Germann UA, Wilson KP, Bemis GW, Fox T, Su MS. Salituro FG, et al. Curr Med Chem. 1999 Sep;6(9):807-23. Curr Med Chem. 1999. PMID: 10495353 Review.
Cited by
- Emodin suppresses alkali burn-induced corneal inflammation and neovascularization by the vascular endothelial growth factor receptor 2 signaling pathway.
Xueying Z, Liang G, Siyi L, Fengyue LI, Mingli L, Wanting L, Chun M, Guanghui L. Xueying Z, et al. J Tradit Chin Med. 2024 Apr;44(2):268-276. doi: 10.19852/j.cnki.jtcm.20240203.005. J Tradit Chin Med. 2024. PMID: 38504533 Free PMC article. - Identification of the key ferroptosis-related genes involved in sepsis progression and experimental validation in vivo.
Li Z, Yu Y, Liu C, Chen G, Gong W, Luo J, Yue Z. Li Z, et al. Front Pharmacol. 2022 Aug 11;13:940261. doi: 10.3389/fphar.2022.940261. eCollection 2022. Front Pharmacol. 2022. PMID: 36188533 Free PMC article. - Priming Is Dispensable for NLRP3 Inflammasome Activation in Human Monocytes In Vitro.
Gritsenko A, Yu S, Martin-Sanchez F, Diaz-Del-Olmo I, Nichols EM, Davis DM, Brough D, Lopez-Castejon G. Gritsenko A, et al. Front Immunol. 2020 Sep 30;11:565924. doi: 10.3389/fimmu.2020.565924. eCollection 2020. Front Immunol. 2020. PMID: 33101286 Free PMC article. - Functions of p38 MAP Kinases in the Central Nervous System.
Asih PR, Prikas E, Stefanoska K, Tan ARP, Ahel HI, Ittner A. Asih PR, et al. Front Mol Neurosci. 2020 Sep 8;13:570586. doi: 10.3389/fnmol.2020.570586. eCollection 2020. Front Mol Neurosci. 2020. PMID: 33013322 Free PMC article. Review. - p38-Mitogen Activated Kinases Mediate a Developmental Regulatory Response to Amino Acid Depletion and Associated Oxidative Stress in Mouse Blastocyst Embryos.
Bora P, Thamodaran V, Šušor A, Bruce AW. Bora P, et al. Front Cell Dev Biol. 2019 Nov 8;7:276. doi: 10.3389/fcell.2019.00276. eCollection 2019. Front Cell Dev Biol. 2019. PMID: 31788473 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous